Prelude Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Prelude Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-280	Closed	-$51K	–	1975
2017 Q1	$51K	Buy	+280	New	+$31.4K	﹤0.01%	978
2015 Q1	–	Sell	-625	Closed	-$496K	–	2300
2014 Q4	$496K	Buy	+625	New	+$336K	0.07%	311
2014 Q2	–	Sell	-500	Closed	-$107K	–	2271
2014 Q1	$109K	Buy	+500	New	+$139K	0.01%	996

Other funds holding TTPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's TTPH Position: Q2 2017 in Review

Prelude Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2017, closing a stake of 280 shares — an estimated $51K sold.

Prelude Capital Management first reported a position in TTPH in Q1 2014 and held it in 3 quarters. The position peaked at $496K in Q4 2014. 90 funds tracked by Wall St. Rank hold TTPH as of Q2 2017.

Prelude Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Prelude Capital Management sold 280 Tetraphase Pharmaceuticals, Inc. shares in Q2 2017, an estimated $51K.
Prelude Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
Prelude Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $496K in Q4 2014.
90 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2017.

Based on Prelude Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.